


CFL-137

Cat. No.:	HY-W016889
CAS No.:	708-06-5
Molecular Formula:	C ₁₁ H ₈ O ₂
Molecular Weight:	172.18
Target:	Ras
Pathway:	GPCR/G Protein
Storage:	4°C, stored under nitrogen
	* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



BIOLOGICAL ACTIVITY

Description	CFL-137 is a potent KRas ^{G12C} inhibitor. CFL-137 shows an antiproliferative effect. CFL-137 shows anticancer activity. CFL-137 has the potential for the research of lung cancer ^[1] .														
IC ₅₀ & Target	KRAS(G12C)														
In Vitro	<p>CFL-137 (72 h) shows an antiproliferative effect with IC₅₀s of 11.4, 24.2, 24.5, 12.3, 43.3, 44.5, 27.63, 32.4, 46.9, 26.2, 25.0, 10.8, 66.2 μM for H1792, SW1573, MiaPaca2, H358, A549, SW480, PANC-1, LCLC-103H, BxPC3, HCA-7, MRC-5, HUVEC-TERT, CCD-986Sk cells, respectively^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>														
In Vivo	<p>CFL-137 (5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments; i.p.) reduces tumor growth in subcutaneous H1792 (KRasG12C mutant) and LCLC-103H (KRasWT) human lung cancer-bearing mice^[1].</p> <p>Pharmacokinetic Parameters of CFL-137 in NOD-SCID female mice^[1].</p> <table border="1"> <thead> <tr> <th>PK parameters</th><th>CFL-137</th></tr> </thead> <tbody> <tr> <td>C_{max} (ng/mL)</td><td>27,366 ± 13,221</td></tr> <tr> <td>T_{max} (h)</td><td>0.25</td></tr> <tr> <td>AUC_t (ng/mL*h)</td><td>28,307 ± 6375</td></tr> <tr> <td>t_{1/2} (h)</td><td>4.0 ± 0.2</td></tr> <tr> <td>V_d (mL)</td><td>63.6 ± 13.6</td></tr> <tr> <td>CL(mL/h)</td><td>11.0 ± 2.8</td></tr> </tbody> </table> <p>NOD-SCID female mice, 15 mg/kg IP^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	PK parameters	CFL-137	C _{max} (ng/mL)	27,366 ± 13,221	T _{max} (h)	0.25	AUC _t (ng/mL*h)	28,307 ± 6375	t _{1/2} (h)	4.0 ± 0.2	V _d (mL)	63.6 ± 13.6	CL(mL/h)	11.0 ± 2.8
PK parameters	CFL-137														
C _{max} (ng/mL)	27,366 ± 13,221														
T _{max} (h)	0.25														
AUC _t (ng/mL*h)	28,307 ± 6375														
t _{1/2} (h)	4.0 ± 0.2														
V _d (mL)	63.6 ± 13.6														
CL(mL/h)	11.0 ± 2.8														

Animal Model:	NOD/SCID female mice (KRasWT (LCLC-103H) or KRasG12C (H1792) tumors) ^[1]
Dosage:	5 mg/kg, 5 treatments; 15 mg/kg, 5 treatments; 30 mg/kg, 3 treatments
Administration:	I.p.
Result:	Reduced tumor growth compared to the control group in KRasG12C mutated model for 32.5%.

REFERENCES

[1]. Orgován Z, et al. Covalent fragment mapping of KRasG12C revealed novel chemotypes with in vivo potency. Eur J Med Chem. 2023 Mar 15;250:115212.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA